AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3396546 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 20
Study 3396546 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 20
Study 31603510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (headache (+) aura (+))
Number of subjects: 130
Study 31603510 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (headache (−) aura (−))
Number of subjects: 130
Study 31603510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (headache (−) aura (+))
Number of subjects: 130
Study 31603510 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (headache (+) aura (−))
Number of subjects: 130
Study 31511054 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 86
Study 31511054 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 86
Study 28364491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Intraindividual Variability (IIV) in Time-in-Bed (TIB)
Number of subjects: 146
Study 28364491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Intraindividual Variability (IIV) in Sleep Onset Latency (SOL)
Number of subjects: 146
Study 28364491 — intervention group
Group type: COMPARATOR
Intervention: Mean Sleep Onset Latency (SOL)
Number of subjects: 146
Study 28364491 — intervention group
Group type: COMPARATOR
Intervention: Bedtime IIV
Number of subjects: 146
Study 28364491 — intervention group
Group type: COMPARATOR
Intervention: Rise time IIV
Number of subjects: 146
Study 25590501 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal death reviews and training on emergency obstetric care
Number of subjects: 191167
Study 25590501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 191167
Study 23732550 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0773 50mg b.i.d.
Number of subjects: 170
Study 23732550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 21692640 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence, high-repetition Soprano® XL laser
Number of subjects: 42
Study 21692640 — intervention group
Group type: COMPARATOR
Intervention: High-fluence, low-repetition LightSheer™ laser
Number of subjects: 42
Study 19110600 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human adenoviruses expressing hypoxia-inducible factors (vascular endothelial growth factor and angiogenin)
Number of subjects: 0
Study 19110600 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 16880093 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HCM
Number of subjects: 30
Study 16880093 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 12599221 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based social support group (Bosom Buddies)
Number of subjects: 72
Study 10639202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22
Study 10639202 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-synchronized nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22
Study 10639202 — intervention group
Group type: COMPARATOR
Intervention: Constant output nebulization (2 mL of 0.5 mg mL(-1) or 2 mL of 0.25 mg mL(-1) budesonide)
Number of subjects: 22
Study 9288387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen economizer tube
Number of subjects: 16
Study 9288387 — intervention group
Group type: COMPARATOR
Intervention: Without oxygen economizer tube
Number of subjects: 16
Study 8347899 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-drug (methylprednisolone and azathioprine)
Number of subjects: 14
Study 8347899 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug (methylprednisolone, azathioprine, and cyclosporine)
Number of subjects: 14
Study 3524910 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus various combinations of ear operations
Number of subjects: 100
Study 3524910 — intervention group
Group type: COMPARATOR
Intervention: Surgery confined to the ears
Number of subjects: 100
Study 3524910 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 100
Study 3524910 — intervention group
Group type: COMPARATOR
Intervention: No adenoidectomy
Number of subjects: 100
Study 31658504 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated positioning system for elution head in TLC/HPTLC-MS
Number of subjects: 70
Study 31658504 — intervention group
Group type: EXPERIMENTAL
Intervention: Elution of butyl paraben zones (5.4%, 10 ng/band)
Number of subjects: 70
Study 28988341 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib monotherapy (AXI)
Number of subjects: 79
Study 28988341 — intervention group
Group type: COMPARATOR
Intervention: Axitinib plus lomustine (AXILOM)
Number of subjects: 79
Study 27529317 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group (infused with acetated Ringer's solution with glucose at 2 mg/kg/min)
Number of subjects: 80
Study 27529317 — intervention group
Group type: COMPARATOR
Intervention: No glucose group (infused with acetated Ringer's solution without glucose)
Number of subjects: 80
Study 27529317 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group
Number of subjects: 80
Study 27529317 — intervention group
Group type: COMPARATOR
Intervention: No glucose group
Number of subjects: 80
Study 24841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose intravenous ozanezumab (0.01, 0.1, 1, 5, or 15 mg/kg)
Number of subjects: 76
Study 24841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat doses of intravenous ozanezumab (0.5, 2.5, or 15 mg/kg)
Number of subjects: 76
Study 24841795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanezumab (0.01-15 mg/kg)
Number of subjects: 76
Study 24841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat dose 15 mg/kg ozanezumab
Number of subjects: 76
Study 24841795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanezumab treatment
Number of subjects: 76
Study 22154769 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV)
Number of subjects: 210
Study 22154769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20482358 — intervention group
Group type: EXPERIMENTAL
Intervention: PubMed search for randomized controlled trials on orthodontic practice
Number of subjects: 161
Study 20482358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality randomized controlled trials identified
Number of subjects: 161
Study 20482358 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication in four orthodontic journals
Number of subjects: 161
Study 17682988 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 infusions of 1 mg/kg (group A)
Number of subjects: 1485
Study 17682988 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 infusions of 0.75 mg/kg (group B)
Number of subjects: 1485
Study 17682988 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 1 mg/kg (group C)
Number of subjects: 1485
Study 17682988 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 0.75 mg/kg (group D)
Number of subjects: 1485
Study 16244023 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron IV
Number of subjects: 105
Study 16244023 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron IV
Number of subjects: 105
Study 16244023 — intervention group
Group type: COMPARATOR
Intervention: 5 mL placebo
Number of subjects: 105
Study 11981704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (USS)
Number of subjects: 93
Study 11981704 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon-beam coagulator (ABC)
Number of subjects: 93
Study 11981704 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery (CEC)
Number of subjects: 93
Study 9446843 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of water (control)
Number of subjects: 0
Study 9446843 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL of table wine (28.4 g ethanol)
Number of subjects: 0
Study 9446843 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mL of table wine (71 g ethanol)
Number of subjects: 0
Study 7648810 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-proliferative retinopathy
Number of subjects: 200
Study 7648810 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative retinopathy
Number of subjects: 200
Study 7648810 — intervention group
Group type: EXPERIMENTAL
Intervention: Males vs Females
Number of subjects: 200
Study 2696457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin titrated to achieve preset 'optimal' active contraction area
Number of subjects: 68
Study 2696457 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin titrated to achieve 'optimal' frequency of contractions
Number of subjects: 68
Study 67975 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered diamorphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Number of subjects: 0
Study 67975 — intervention group
Group type: COMPARATOR
Intervention: Orally administered morphine every four hours at individually optimized doses in association with cocaine and a phenothiazine
Number of subjects: 0
Study 30633317 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia using 25 and 26 gauge quincke and pencil-point spinal needles
Number of subjects: 613
Study 30633317 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 613
Study 30633317 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician experience and physical condition
Number of subjects: 613
Study 29197204 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM rehabilitation exercises
Number of subjects: 162
Study 29197204 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 162
Study 25966305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicon(®) implants (6 or 8 mm)
Number of subjects: 20
Study 25966305 — intervention group
Group type: COMPARATOR
Intervention: Ankylos(®) implants (8 mm)
Number of subjects: 20
Study 24232701 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme
Number of subjects: 33
Study 24232701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 22960769 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist started on day 1 of stimulation (Group 1)
Number of subjects: 140
Study 22960769 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist started on day 5 of stimulation (Group 2)
Number of subjects: 140
Study 20582874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin protein (0.6 g protein per kg bodyweight)
Number of subjects: 16
Study 20582874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 16
Study 20582874 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH injection (1 mu/kg body weight)
Number of subjects: 16
Study 17019083 — intervention group
Group type: EXPERIMENTAL
Intervention: FX06 injection during and immediately after primary PCI
Number of subjects: 0
Study 17019083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16061577 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient family therapy for 6 months
Number of subjects: 22
Study 16061577 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention program
Number of subjects: 22
Study 16061577 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient family therapy
Number of subjects: 22
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (0.5 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (2 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA‐4Ig (10 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA29Y (0.5 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA29Y (2 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA29Y (10 mg/kg)
Number of subjects: 214
Study 12115176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 10198864 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% drops (3 preoperative drops given 10 minutes apart)
Number of subjects: 31
Study 10198864 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shield soaked in ofloxacin 0.3%
Number of subjects: 31
Study 7774989 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily
Number of subjects: 27
Study 7774989 — intervention group
Group type: COMPARATOR
Intervention: lovastatin 40‐80 mg once daily
Number of subjects: 27
Study 1536333 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 15-minute telephone calls approximately 1 to 3 weeks apart
Number of subjects: 0
Study 1536333 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 0
Study 6380974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol
Number of subjects: 28
Study 6380974 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 28
Study 30819614 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonizing stomach to tranquilize mind acupuncture
Number of subjects: 60
Study 30819614 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 28925405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (INT)
Number of subjects: 51
Study 28925405 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CON)
Number of subjects: 51
Study 26928727 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin, statin and two antihypertensives)
Number of subjects: 413
Study 26928727 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study 28341619 — intervention group
Group type: EXPERIMENTAL
Intervention: ERPonline plus usual treatment
Number of subjects: 96
Study 28341619 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) control plus usual treatment
Number of subjects: 96
Study 22906798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy (initial dose: 600mg/d, adjusted to therapeutic levels)
Number of subjects: 46
Study 21093140 — intervention group
Group type: COMPARATOR
Intervention: Standard Insertion Technique (SIT)
Number of subjects: 70
Study 21093140 — intervention group
Group type: COMPARATOR
Intervention: Standard Insertion Technique with Jaw Thrust (SIT/JT)
Number of subjects: 70
Study 21093140 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Jaw Thrust Insertion Technique (FIT/JT)
Number of subjects: 70
Study 19157547 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry (FCM)
Number of subjects: 8
Study 19157547 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative PCR of IG/TCR gene rearrangements
Number of subjects: 8
Study 19157547 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR detecting fusion gene transcripts
Number of subjects: 8
Study 19157547 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR‐ABL1 RNA level
Number of subjects: 8
Study 19157547 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry (FCM) and IG/TCR rearrangement quantification
Number of subjects: 8
Study 17150416 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with interferon‐alpha
Number of subjects: 8
Study 17150416 — intervention group
Group type: COMPARATOR
Intervention: Monoimmunotherapy with interferon‐alpha applied three times weekly for a total of 4 weeks
Number of subjects: 8
Study 15520346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine offered group
Number of subjects: 437
Study 15520346 — intervention group
Group type: COMPARATOR
Intervention: Education only group
Number of subjects: 437
Study 11281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Number of subjects: 245
Study 11281461 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 microgm, administered four hourly to a maximum of five doses)
Number of subjects: 245
Study 11281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 245
Study 11281461 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 245
Study 9771866 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg Ca/d as calcium citrate malate)
Number of subjects: 354
Study 9771866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 7787753 — intervention group
Group type: EXPERIMENTAL
Intervention: All transretinoic acid (ATRA) combined with intensive chemotherapy
Number of subjects: 0
Study 7787753 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 0
Study 2159696 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 g sodium propionate daily in capsule form
Number of subjects: 10
Study 2159696 — intervention group
Group type: COMPARATOR
Intervention: Dibasic calcium phosphate (placebo)
Number of subjects: 10
Study 6784978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 microgram . kg‐1 . min‐1)
Number of subjects: 5
Study 6784978 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (20 mg infused over 3 h)
Number of subjects: 5
Study 31154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Free water protocol (access to water and ice)
Number of subjects: 104
Study 31154338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to water and ice)
Number of subjects: 104
Study 31154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up patients in rehabilitation (n = 15)
Number of subjects: 104
Study 28892457 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg monthly for 12 months)
Number of subjects: 4093
Study 28892457 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg weekly for 12 months)
Number of subjects: 4093
Study 25794186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fluorescent phototherapy
Number of subjects: 42
Study 25794186 — intervention group
Group type: EXPERIMENTAL
Intervention: Double fluorescent phototherapy
Number of subjects: 42
Study 25794186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single unit photodiodes
Number of subjects: 42
Study 25794186 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 42
Study 23348977 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening strategy of the NELSON trial
Number of subjects: 200
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (specifically SNPs rs873457, rs2336384, rs1474868, rs4846085, rs2236055)
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (specifically SNP rs4240897)
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (dominant model)
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (subgroup by sex)
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: HSG/Mfn2 gene polymorphism (allelic frequency of rs4240897)
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: C‐G‐A‐A‐A‐C‐C haplotype
Number of subjects: 1081
Study 20940517 — intervention group
Group type: COMPARATOR
Intervention: Other haplotypes
Number of subjects: 1081
Study 20940517 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and rs873457
Number of subjects: 1081
Study 19217717 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time multidisciplinary programme (MDP)
Number of subjects: 2
Study 19217717 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic manual therapy and exercise programme (OMTP)
Number of subjects: 2
Study 19217717 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 2
Study 17086362 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus niacin
Number of subjects: 34
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin-T quartiles
Number of subjects: 7800
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein quartiles
Number of subjects: 7800
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP elevation
Number of subjects: 7800
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 7800
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-depression at admission
Number of subjects: 7800
Study 15150954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimarker strategy (creatinine clearance, troponin, CRP, NT-proBNP, ischemic ECG changes, clinical background characteristics)
Number of subjects: 7800
Study 11222107 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐labelled diethylenetriaminepenta‐acetic acid (DTPA)
Number of subjects: 17
Study 11222107 — intervention group
Group type: EXPERIMENTAL
Intervention: (113m)In‐labelled biotinylated DTPA (B‐DTPA)
Number of subjects: 17
Study 11222107 — intervention group
Group type: COMPARATOR
Intervention: Comparison of clearance rates of DTPA and B-DTPA
Number of subjects: 17
Study 9363520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported diagnoses
Number of subjects: 5632
Study 9363520 — intervention group
Group type: COMPARATOR
Intervention: Clinical confirmation by a specialist
Number of subjects: 5632
Study 7911177 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms gD2 in alum
Number of subjects: 98
Study 7911177 — intervention group
Group type: COMPARATOR
Intervention: alum alone (placebo)
Number of subjects: 98
Study 2402207 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (1 g.kg‐1 body weight) plus water (21.4 ml.kg‐1 body weight)
Number of subjects: 6
Study 2402207 — intervention group
Group type: COMPARATOR
Intervention: Water (21.4 ml.kg‐1)
Number of subjects: 6
Study 2402207 — intervention group
Group type: COMPARATOR
Intervention: Water (3.3 ml.kg‐1)
Number of subjects: 6